302 related articles for article (PubMed ID: 30345704)
1. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis.
Ponziani FR; Putignani L; Paroni Sterbini F; Petito V; Picca A; Del Chierico F; Reddel S; Calvani R; Marzetti E; Sanguinetti M; Gasbarrini A; Pompili M
Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1301-1311. PubMed ID: 30345704
[TBL] [Abstract][Full Text] [Related]
2. Short-term effects of direct-acting antiviral agents on inflammation and gut microbiota in hepatitis C-infected patients.
Pérez-Matute P; Íñiguez M; Villanueva-Millán MJ; Recio-Fernández E; Vázquez AM; Sánchez SC; Morano LE; Oteo JA
Eur J Intern Med; 2019 Sep; 67():47-58. PubMed ID: 31221551
[TBL] [Abstract][Full Text] [Related]
3. Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis.
Wellhöner F; Döscher N; Woelfl F; Vital M; Plumeier I; Kahl S; Potthoff A; Manns MP; Pieper DH; Cornberg M; Wedemeyer H; Heidrich B
Hepatology; 2021 Jul; 74(1):72-82. PubMed ID: 33411981
[TBL] [Abstract][Full Text] [Related]
4. Microbiota and hepatitis C virus in the era of direct-acting antiviral agents.
Pinchera B; Moriello NS; Buonomo AR; Zappulo E; Viceconte G; Villari R; Gentile I
Microb Pathog; 2023 Feb; 175():105968. PubMed ID: 36626945
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of serum α-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals.
Fouad R; Elsharkawy A; Abdel Alem S; El Kassas M; Alboraie M; Sweedy A; Afify S; Abdellatif Z; Khairy M; Esmat G
Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1129-1134. PubMed ID: 30896550
[TBL] [Abstract][Full Text] [Related]
6. Microbial translocation and T cell activation are modified by direct-acting antiviral therapy in HCV-infected patients.
Lattanzi B; Baroncelli S; De Santis A; Galluzzo CM; Mennini G; Michelini Z; Lupo M; Ginanni Corradini S; Rossi M; Palmisano L; Merli M
Aliment Pharmacol Ther; 2018 Nov; 48(10):1146-1155. PubMed ID: 30294870
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
[TBL] [Abstract][Full Text] [Related]
9. HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients.
Bajaj JS; Sterling RK; Betrapally NS; Nixon DE; Fuchs M; Daita K; Heuman DM; Sikaroodi M; Hylemon PB; White MB; Ganapathy D; Gillevet PM
Aliment Pharmacol Ther; 2016 Sep; 44(6):638-43. PubMed ID: 27417456
[TBL] [Abstract][Full Text] [Related]
10. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
11. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025.
Rodríguez-Tajes S; Pocurull A; Castillo J; Casanova G; Vega L; Lens S; Mariño Z; Londoño MC; Forner A; Torres F; Forns X
J Hepatol; 2020 Dec; 73(6):1360-1367. PubMed ID: 32697948
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Plasma Tenascin-C in Post-HCV Cirrhosis: A Prospective Study.
Benbow JH; Elam AD; Bossi KL; Massengill DL; Brandon-Warner E; Anderson WE; Culberson CR; Russo MW; deLemos AS; Schrum LW
Dig Dis Sci; 2018 Mar; 63(3):653-664. PubMed ID: 29330728
[TBL] [Abstract][Full Text] [Related]
14. Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens.
Attia D; Deterding K; Cornberg J; Gebel MJ; Cornberg M; Manns MP; Wedemeyer H; Potthoff A
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):67-74. PubMed ID: 30239347
[TBL] [Abstract][Full Text] [Related]
15. Effects of direct anti-viral agents on the gut microbiota in patients with chronic hepatitis C.
Huang PY; Chen CH; Tsai MJ; Yao CC; Wang HM; Kuo YH; Chang KC; Hung CH; Chuah SK; Tsai MC
J Formos Med Assoc; 2023 Feb; 122(2):157-163. PubMed ID: 36155707
[TBL] [Abstract][Full Text] [Related]
16. Impact of direct acting antiviral (DAA) treatment on glucose metabolism and reduction of pre-diabetes in patients with chronic hepatitis C.
Weidner P; Boettche D; Zimmerer T; Burgermeister E; Teufel A; Ebert MPA; Antoni C
J Gastrointestin Liver Dis; 2018 Sep; 27(3):281-289. PubMed ID: 30240472
[TBL] [Abstract][Full Text] [Related]
17. Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals.
Tajiri K; Okada K; Ito H; Kawai K; Kashii Y; Tokimitsu Y; Muraishi N; Murayama A; Hayashi Y; Minemura M; Takahara T; Shimizu Y; Yasuda I
BMC Gastroenterol; 2023 May; 23(1):182. PubMed ID: 37231349
[TBL] [Abstract][Full Text] [Related]
18. Benefits of hepatitis C cure with antivirals: why test and treat?
Lledó G; Benítez-Gutiérrez L; Arias A; Requena S; Cuervas-Mons V; de Mendoza C
Future Microbiol; 2019 Mar; 14():425-435. PubMed ID: 30900911
[TBL] [Abstract][Full Text] [Related]
19. Real-world single-center experience with direct-acting antivirals for improvement of the liver fibrosis after chronic hepatitis C treatment.
Lee SH; Shin HP; Lee JI
Antivir Chem Chemother; 2020; 28():2040206620974835. PubMed ID: 33215505
[TBL] [Abstract][Full Text] [Related]
20. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
